*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**MicroPort NeuroScientific Corporation**
**微創腦科學有限公司**
*(Incorporated in the Cayman Islands with limited liability)*
**(Stock Code: 2172)**

# VOLUNTARY ANNOUNCEMENT
# NUMEN™ Helia COIL RECEIVES APPROVAL FROM FDA FOR MARKETING

This announcement is made by MicroPort NeuroScientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors (the "**Board**") of the Company is pleased to announce that NUMEN™ Helia Coil Embolization System ("**NUMEN™ Helia**"), independently developed by MicroPort NeuroTech (Shanghai) Co., Ltd., a subsidiary of the Group, has recently received approval from the United States Food and Drug Administration ("**FDA**") for marketing.

This approval marks the third coil product of the Group to be approved for marketing in the United States, following the NUMEN™ Detachable Coil and the NUMEN™ Silk Coil Embolization System. It further enhances the Group's product portfolio in the neuro-interventional embolization field in North America and reflects the Group's continuous breakthroughs in the research and development of innovative neuro-interventional products and international registration.

NUMEN™ Helia is intended to endovascularly obstruct or occlude blood flow in vascular abnormalities of the neurovascular vessels. Compared with the currently marketed NUMEN™ series coils products, NUMEN™ Helia features as "longer, thinner, and softer". It is compatible with 0.013-inch microcatheters and is suitable for delivery and embolization operations in small, tortuous, or access-constrained vessels, offering a more refined solution for the treatment of complex vascular lesions.

The key design advantages of NUMEN™ Helia include:

- **Optimized adaptability to complex vasculature**

  Its unique Cube/Spiral structural configuration enhances wall anchoring performance, enabling smoother delivery and natural conformance in small and complex vascular environments.

- **Support for efficient and dense packing**

  The product covers diameters ranging from 1mm to 3.5mm, with lengths up to 60cm, and offers a variety of extended-length configurations, assisting operators in achieving more efficient and precise packing operations in small vessels.

- **Enhanced minimally invasive operation experience**

  The ultra-soft coil design meets the delivery requirements of small vessels and complex access routes, helping to improve embolization operations efficiency and optimize clinical operation experience.

This approval of NUMEN™ Helia by FDA further enriches the Group's product matrix in the neuro-interventional market in the United States. Its design features will help meet a wider range of clinical needs for neurovascular embolization therapy, enhancing the Group's product strength and competitive advantage in the neuro-interventional market in the United States. Looking ahead, the Group will continue to focus on the therapeutic needs of neurovascular diseases, accelerate the global registration and commercialization of innovative products, and continuously refine comprehensive neuro-interventional solutions, providing physicians and patients worldwide with higher-quality and more accessible treatment options.

There can be no assurance that NUMEN™ Helia will eventually be successfully commercialized. Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By Order of the Board
**MicroPort NeuroScientific Corporation**
**Dr. Zhang Jie**
*Chairman and Non-executive Director*

Hong Kong, May 25, 2026

*As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Zhang Jie, Mr. Liu Xudong and Ms. Wu Xia as the non-executive directors; Dr. Zhang Haixiao, Mr. Fan Xin, Mr. Li Zhiyong and Mr. Liu Thomas A. as the independent non-executive directors.*